CD8a Monoclonal Antibody (4SM15), eBioscience™ | Invitrogen 14-0808-95 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

CD8a Monoclonal Antibody (4SM15), eBioscience™

catalog :

14-0808-95

quantity :

10 mg

price :

US 3430

clonality :

monoclonal

host :

rat

conjugate :

nonconjugated

clone name :

4SM15

reactivity :

mouse

application :

immunohistochemistry, flow cytometry, immunohistochemistry - paraffin section

citations: 32

Reference
Schreiber L, Urbiola C, Das K, Spiesschaert B, Kimpel J, Heinemann F, et al. The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer. Br J Cancer. 2019;121:647-658 pubmed publisher
Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019;9:1853 pubmed publisher
Morrison M, Verschuren L, Salic K, Verheij J, Menke A, Wielinga P, et al. Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-.Leiden Mice. Hepatol Commun. 2018;2:1513-1532 pubmed publisher
Lu J, Liu X, Liao Y, Wang X, Ahmed A, Jiang W, et al. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. ACS Nano. 2018;12:11041-11061 pubmed publisher
Yu J, Bhattacharya S, Yanamandra N, Kilian D, Shi H, Yadavilli S, et al. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS ONE. 2018;13:e0206223 pubmed publisher
Messenger Z, Hall J, Jima D, House J, Tam H, Tokarz D, et al. C/EBPβ deletion in oncogenic Ras skin tumors is a synthetic lethal event. Cell Death Dis. 2018;9:1054 pubmed publisher
Seo J, Tavare R, Mahakian L, Silvestrini M, Tam S, Ingham E, et al. CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res. 2018;24:4976-4987 pubmed publisher
Ubil E, Caskey L, Holtzhausen A, Hunter D, Story C, Earp H. Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest. 2018;128:2356-2369 pubmed publisher
Mi Y, Smith C, Yang F, Qi Y, Roche K, Serody J, et al. A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy. Adv Mater. 2018;30:e1706098 pubmed publisher
Suárez López L, Sriram G, Kong Y, Morandell S, Merrick K, Hernandez Y, et al. MK2 contributes to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis. Proc Natl Acad Sci U S A. 2018;115:E4236-E4244 pubmed publisher
McGrail D, Federico L, Li Y, Dai H, Lu Y, Mills G, et al. Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun. 2018;9:1317 pubmed publisher
Yan X, Wang L, Zhang R, Pu X, Wu S, Yu L, et al. Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. Oncoimmunology. 2017;7:e1376156 pubmed publisher
Topper M, Vaz M, Chiappinelli K, Destefano Shields C, Niknafs N, Yen R, et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell. 2017;171:1284-1300.e21 pubmed publisher
Lu J, Liu X, Liao Y, Salazar F, Sun B, Jiang W, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun. 2017;8:1811 pubmed publisher
Unver N, Delgado O, Zeleke K, Cumpian A, Tang X, Caetano M, et al. Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol. Int J Cancer. 2017;: pubmed publisher
Beigier Bompadre M, Montagna G, Kuhl A, Lozza L, Weiner J, Kupz A, et al. Mycobacterium tuberculosis infection modulates adipose tissue biology. PLoS Pathog. 2017;13:e1006676 pubmed publisher
da Silva J, Moreira Dos Santos T, Sobral L, Queiroz Junior C, Rachid M, Proudfoot A, et al. Relevance of CCL3/CCR5 axis in oral carcinogenesis. Oncotarget. 2017;8:51024-51036 pubmed publisher
Mori H, Chen J, Cardiff R, PÃ©nzvÃ¡ltÃ³ Z, Hubbard N, Schuetter L, et al. Pathobiology of the 129:Stat1 -/- mouse model of human age-related ER-positive breast cancer with an immune infiltrate-excluded phenotype. Breast Cancer Res. 2017;19:102 pubmed publisher
Manguso R, Pope H, Zimmer M, Brown F, Yates K, Miller B, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547:413-418 pubmed publisher
Rashidian M, Ingram J, Dougan M, Dongre A, Whang K, LeGall C, et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017;214:2243-2255 pubmed publisher
Jaini R, Loya M, Eng C. Immunotherapeutic target expression on breast tumors can be amplified by hormone receptor antagonism: a novel strategy for enhancing efficacy of targeted immunotherapy. Oncotarget. 2017;8:32536-32549 pubmed publisher
Guo Q, Minnier J, Burchard J, Chiotti K, Spellman P, Schedin P. Physiologically activated mammary fibroblasts promote postpartum mammary cancer. JCI Insight. 2017;2:e89206 pubmed publisher
Rios Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, MARRERO A, et al. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Res. 2017;77:2686-2698 pubmed publisher
Pishesha N, Bilate A, Wibowo M, Huang N, Li Z, Deshycka R, et al. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease. Proc Natl Acad Sci U S A. 2017;114:3157-3162 pubmed publisher
Bansal S, Ismahil M, Goel M, Patel B, Hamid T, Rokosh G, et al. Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure. Circ Heart Fail. 2017;10:e003688 pubmed publisher
Tang X, Wang X, Zhao Y, Curtis J, Brindley D. Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-?B activation. Mol Cancer. 2017;16:36 pubmed publisher
Li L, Wang W, Pan H, Ma G, Shi X, Xie H, et al. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer. J Transl Med. 2017;15:23 pubmed publisher
Antonios J, Soto H, Everson R, Moughon D, Orpilla J, Shin N, et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017;19:796-807 pubmed publisher
Qi X, Lam S, Liu D, Kim D, Ma L, Alleruzzo L, et al. Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. J Clin Cell Immunol. 2016;7: pubmed publisher
Lhotak S, Gyulay G, Cutz J, Al Hashimi A, Trigatti B, Richards C, et al. Characterization of Proliferating Lesion-Resident Cells During All Stages of Atherosclerotic Growth. J Am Heart Assoc. 2016;5: pubmed publisher
Marek I, Lichtneger T, Cordasic N, Hilgers K, Volkert G, Fahlbusch F, et al. Alpha8 Integrin (Itga8) Signalling Attenuates Chronic Renal Interstitial Fibrosis by Reducing Fibroblast Activation, Not by Interfering with Regulation of Cell Turnover. PLoS ONE. 2016;11:e0150471 pubmed publisher
Wang D, Mou H, Li S, Li Y, Hough S, Tran K, et al. Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. Hum Gene Ther. 2015;26:432-42 pubmed publisher

product information

Product Type :

Antibody

Product Name :

CD8a Monoclonal Antibody (4SM15), eBioscience™

Catalog # :

14-0808-95

Quantity :

10 mg

Price :

US 3430

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Rat

Reactivity :

Mouse

Applications :

Flow Cytometry: 0.25 µg/test, Immunohistochemistry (Paraffin): 5 µg/mL

Species :

Mouse

Clone :

4SM15

Isotype :

IgG2a, lambda

Storage :

4° C

Description :

CD8 molecule is composed of two chains termed alpha and beta. CD8 is found on a T cell subset of normal cytotoxic / suppressor cells which make up approximately 20 to 35% of human peripheral blood lymphocytes. The CD8 antigen is also detected on natural killer cells, 80% of thymocytes, on a subpopulation of 30% of peripheral blood null cells and 15 to 30% of bone marrow cells.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 0.25 µg/test, Immunohistochemistry (Paraffin): 5 µg/mL

Aliases :

BB154331; CD8; CD8 alpha; CD8 alpha chain; CD8 alpha chain-like; CD8 antigen 32 kDa chain; CD8 antigen 37 kDa chain; CD8 antigen alpha polypeptide; CD8 antigen alpha protein; CD8 antigen alpha protein precursor; CD8 antigen alpha-chain; CD8 antigen beta polypeptide; CD8 antigen beta polypeptide precursor; CD8 antigen beta-chain; CD8 antigen, alpha chain; CD8 antigen, alpha polypeptide; CD8 antigen, alpha polypeptide (p32); CD8 antigen, alpha-chain; CD8 antigen, beta chain; CD8 antigen, beta chain 1; CD8 antigen, beta polypeptide; CD8 antigen, beta polypeptide 1 (p37); CD8 antigen, beta-chain; CD8 beta; CD8 beta chain; CD8 beta-2; CD8A; CD8a molecule; CD8A; T-cell surface glycoprotein; CD8alpha; CD8B; CD8b antigen; CD8b molecule; Cd8b1; CD8beta; fCD8; LEU2; Leu-2; Leu2 T-lymphocyte antigen; leu-2a; LOC100356269; Ly-2; LY3; Ly-3; Ly-35; Ly-B; Ly-C; Lymphocyte antigen 3; Lyt2; Lyt-2; Lyt-2.1 lymphocyte differentiation antigen (AA at 100); Lyt3; Lyt-3; MAL; OKT8 T-cell antigen; OX-8 membrane antigen; p32; P37; RHACD8-4; T cell co-receptor; T lymphocyte surface glycoprotein beta chain; T8 T-cell antigen; T-cell antigen Leu2; T-cell membrane glycoprotein Ly-3; T-cell surface glycoprotein; T-cell surface glycoprotein CD8 alpha chain; T-cell surface glycoprotein CD8 beta chain; T-cell surface glycoprotein Lyt-2; T-cell surface glycoprotein Lyt-3; T-cell surface molecule; T-lymphocyte differentiation antigen T8/Leu-2